Aevumed, Inc. appears in FDA records as the applicant for K253065, the Aevumed SUPERCYNCH™ Button System, received September 22, 2025, and found substantially equivalent on September 2, 2026. The submission is a Traditional 510(k) reviewed by the Orthopedic panel under 21 CFR 888.3040, product code MBI, device class 2, with a Summary statement. The supplied filing collection contains one linked record, and that record carries a substantially equivalent decision. The company's own site describes SUPERCYNCH as a knotless biceps tenodesis button with a mechanical flipping mechanism and unidirectional tensioning, built in titanium with a 3.2 mm drill size. [1][3][8]
The documented 510(k) record
K253065 lists Aevumed, Inc. as applicant at an address in Malvern, Pennsylvania, with Saif Khalil as contact. The device is classified as a nondegradable soft-tissue fixation fastener, regulation 888.3040, class 2, advisory committee Orthopedic. The decision code is SESE, described as Substantially Equivalent, dated September 2, 2026, and the clearance type is Traditional with no third-party review. [1][8]
The stated indications cover fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee, hand/wrist, and further anatomical sites listed in the filing. A third-party device summary reports a 345-day review interval from receipt to the September 2, 2026 decision and no recalls tied to K253065 in FDA's recall database as of November 17, 2026. The supplied portfolio snapshot likewise contains no recall records. [7][8]
Product detail as published by Aevumed
Aevumed's product page describes SUPERCYNCH as a biceps tenodesis button with a knotless self-cinching mechanism, a mechanical flipping mechanism for 90-degree actuation, tactile deployment feedback, unidirectional tensioning, and a small titanium profile. Listed specifications are titanium material and a 3.2 mm drill size, with biceps tenodesis as the indication. These are the company's own descriptions, not independently verified performance data. [3]
The same page labels the device FDA Cleared SUPERCYNCH™, consistent with the K253065 decision. The company's product index lists other named devices with their own clearance labels, including PHANTOM® and PHANTOM®-LP suture anchors marked FDA Cleared and PHANTOM®-X marked Not FDA Cleared. Those labels belong to separate products and do not extend to or from K253065. [3][4]
Company positioning and stated approach
Aevumed describes itself as a medical device company specializing in orthopedic solutions for soft tissue repair and regeneration, working through minimally invasive implants, biologics, proprietary AI, and collaboration with surgeons. The company states that products are shaped by the surgeons who use them and refined with Medical and Surgeon Advisory Boards. It also markets AiTRIUM™, described as a surgical intelligence platform. [5][6]
These are company-published claims about its own business and development approach. The public documents do not establish ownership, parent entities, commercial availability, customer relationships, or clinical outcomes, and the Malvern, Pennsylvania address in the FDA filing is a filing address rather than a verified headquarters. [1][3][6]
What the filing collection does and does not show
The MedtechLedger snapshot links one 510(k) record to Aevumed, with one substantially equivalent decision, and no premarket approval or De Novo records. That count reflects the retrieved filings at the snapshot time, not the company's total portfolio, sales, or safety performance. The record sample is the same single entry, so the full collection and the sample share one denominator here. [1]
The K253065 record does not disclose predicate device numbers, clinical study results, or shelf-life and sterilization details in the public information. A third-party page references other suture anchor clearances by different applicants, which are unrelated to Aevumed's own submissions and are not evidence of Aevumed filings. [7][8]

